21:23 , Nov 10, 2017 |  BC Week In Review  |  Company News

Valeant divests Sprout back to former owners

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said it will divest its Sprout Pharmaceuticals Inc. subsidiary back to Sprout's former shareholders. The deal is expected to close by year end. In 2015, Valeant acquired Sprout for...
22:26 , Nov 6, 2017 |  BC Extra  |  Company News

Valeant divests Sprout back to former owners

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said it will divest its Sprout Pharmaceuticals Inc. subsidiary back to Sprout's former shareholders. The deal is expected to close by year end. In 2015, Valeant acquired Sprout for...
08:00 , Nov 2, 2015 |  BC Week In Review  |  Company News

Valeant Pharmaceuticals sales and marketing update

Valeant’s Sprout Pharmaceuticals Inc. division launched Addyi flibanserin in the U.S. to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The wholesale acquisition cost (WAC) for the serotonin (5-HT1A) receptor agonist and...
07:00 , Aug 24, 2015 |  BC Week In Review  |  Company News

Sprout Pharmaceuticals, Valeant Pharmaceuticals deal

Valeant will acquire Sprout for $1 billion in cash. Last week, FDA approved Addyi flibanserin, a serotonin (5-HT1A) receptor agonist and 5-HT2A receptor antagonist, from Sprout to treat acquired, generalized hypoactive sexual desire disorder (HSDD)...
07:00 , Aug 24, 2015 |  BC Week In Review  |  Clinical News

Flibanserin regulatory update

FDA approved an NDA from Sprout for Addyi flibanserin to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The company said it plans to launch the serotonin (5-HT1A) receptor agonist and 5-HT2A...
01:09 , Aug 21, 2015 |  BC Extra  |  Company News

Valeant to acquire Sprout

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) said it will acquire Sprout Pharmaceuticals Inc. (Raleigh, N.C.) for $1 billion in cash. FDA approved Sprout's female sexual dysfunction treatment Addyi flibanserin on Tuesday. Valeant said it would...
00:51 , Aug 19, 2015 |  BC Extra  |  Company News

FDA approves first drug for sexual desire disorder

FDA approved Addyi flibanserin from Sprout Pharmaceuticals Inc. (Raleigh, N.C.) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. The agency said Addyi is the first drug approved for the indication. Sprout...
07:00 , Jun 15, 2015 |  BC Week In Review  |  Clinical News

Addyi flibanserin regulatory update

FDA’s Bone, Reproductive and Urologic Drugs and Drug Safety and Risk Management advisory committees voted 18-6 that the benefit/risk profile of Addyi flibanserin from Sprout supports approval to treat hypoactive sexual desire disorder (HSDD) in...
02:08 , Jun 5, 2015 |  BC Extra  |  Company News

FDA panel backs flibanserin approval with risk-mitigating plans

FDA's Bone, Reproductive and Urologic Drugs and Drug Safety and Risk Management advisory committees voted 18-6 that the benefit/risk profile of flibanserin from Sprout Pharmaceuticals Inc. (Raleigh, N.C.) supports its approval to treat hypoactive sexual...
07:00 , May 18, 2015 |  BC Week In Review  |  Clinical News

Flibanserin regulatory update

FDA’s Bone, Reproductive and Urologic Drugs and Drug Safety and Risk Management advisory committees will meet on June 4 to discuss a resubmitted NDA from Sprout for flibanserin to treat hypoactive sexual desire disorder (HSDD)...